CY2498B1 - Nucleosides and oligonucleotides containing 2'-ether groups. - Google Patents

Nucleosides and oligonucleotides containing 2'-ether groups.

Info

Publication number
CY2498B1
CY2498B1 CY0400093A CY0400093A CY2498B1 CY 2498 B1 CY2498 B1 CY 2498B1 CY 0400093 A CY0400093 A CY 0400093A CY 0400093 A CY0400093 A CY 0400093A CY 2498 B1 CY2498 B1 CY 2498B1
Authority
CY
Cyprus
Prior art keywords
formula
nucleosides
ether groups
oligonucleotides containing
protecting
Prior art date
Application number
CY0400093A
Other languages
English (en)
Inventor
Pierre Dr Martin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2498B1 publication Critical patent/CY2498B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CY0400093A 1994-04-27 2004-12-27 Nucleosides and oligonucleotides containing 2'-ether groups. CY2498B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH130794 1994-04-27

Publications (1)

Publication Number Publication Date
CY2498B1 true CY2498B1 (en) 2005-09-02

Family

ID=4207379

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400093A CY2498B1 (en) 1994-04-27 2004-12-27 Nucleosides and oligonucleotides containing 2'-ether groups.

Country Status (15)

Country Link
US (2) US5750673A (fr)
EP (1) EP0679657B1 (fr)
JP (1) JPH07300493A (fr)
KR (1) KR950032263A (fr)
CN (1) CN1066456C (fr)
AT (1) ATE244723T1 (fr)
AU (1) AU682576B2 (fr)
CA (1) CA2147798A1 (fr)
CY (1) CY2498B1 (fr)
DE (1) DE59510742D1 (fr)
DK (1) DK0679657T3 (fr)
ES (1) ES2203635T3 (fr)
IL (1) IL113482A0 (fr)
PT (1) PT679657E (fr)
ZA (1) ZA953383B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0942000T3 (da) 1989-10-24 2004-11-01 Isis Pharmaceuticals Inc 2'-modificerede oligonukleotider
DE59510742D1 (de) * 1994-04-27 2003-08-14 Novartis Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0813539B1 (fr) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Procede ameliore pour la synthese des pyrimidines a substitution 2'-o et de leurs composes oligomeres
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
WO1997037993A1 (fr) * 1996-04-09 1997-10-16 Yamasa Corporation DERIVES DE 9-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)PURINE
AU3029797A (en) * 1996-06-06 1998-01-05 Novartis Ag 2'-substituted nucleosides and oligonucleotide derivatives
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
FR2788524B1 (fr) * 1999-01-18 2002-04-26 Merial Sas Procede utile pour transformer la fonction 4"(s)-oh du motif cladinose d'un aza macrolide en 4"(r)-nh2
AR025996A1 (es) 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
US7425547B2 (en) * 2002-09-30 2008-09-16 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
KR100481356B1 (ko) * 2002-10-17 2005-04-07 이수화학 주식회사 2'-ｏ-치환된 뉴클레오시드의 제조 방법
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US7947817B2 (en) * 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
WO2005044835A1 (fr) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Procedes de preparation de derives 7-(2'-$g(b)-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US7745125B2 (en) * 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
UA99594C2 (en) 2006-01-12 2012-09-10 Сайбас Юроп Б.В. Epsps mutants
US8029579B2 (en) 2006-06-28 2011-10-04 COH Inc. Fatty acid blends and uses therefor
US7820810B2 (en) * 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
PL2700721T3 (pl) 2007-10-05 2019-06-28 Cibus Europe B.V. Zmutowane geny kodujące syntazę kwasu acetohydroksylowego w brassica
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AU2009248852B9 (en) 2008-05-23 2015-08-13 Cibus Europe B.V. Production of squalene using yeast
JP5438922B2 (ja) * 2008-06-25 2014-03-12 日東電工株式会社 核酸の製造方法
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
CA2741294C (fr) * 2008-10-24 2018-04-24 Isis Pharmaceuticals, Inc. Nucleotides bis-substitues en 5' et 2' et composes oligomeres prepares a partir de ceux-ci
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
AR077859A1 (es) 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
EP3219815B1 (fr) 2009-11-23 2019-10-02 Cibus Europe B.V. Procédés et compositions de production de squalène au moyen de la levure
US20120122223A1 (en) 2010-08-03 2012-05-17 Cibus Us Llc Mutated protoporphyrinogen ix oxidase (ppx) genes
UA112969C2 (uk) 2010-08-03 2016-11-25 Сібас Юс Ллс Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх)
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2014153178A2 (fr) 2013-03-14 2014-09-25 Cibus Us Llc Gènes d'oxyde d'allène synthase 2 (aos2) mutés
LT3527068T (lt) 2013-03-15 2022-08-10 Cibus Us Llc Būdai ir kompozicijos, skirti padidinti tikslinės geno modifikacijos efektyvumą, panaudojant geno reparaciją, kuriai tarpininkauja oligonukleotidas
PL2966984T3 (pl) 2013-03-15 2022-06-13 Cibus Us Llc Ukierunkowana modyfikacja genu z użyciem naprawy genu, w której pośredniczy oligonukleotyd
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
US12331303B2 (en) 2013-03-15 2025-06-17 Cibus Us Llc Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
ES2974625T3 (es) 2014-03-14 2024-06-28 Cibus Us Llc Procedimientos y composiciones para aumentar la eficacia de la modificación génica dirigida mediante reparación génica mediada por oligonucleótidos
KR102841205B1 (ko) 2016-02-09 2025-08-01 시버스 유에스 엘엘씨 올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물
EP3491001A1 (fr) 2016-07-27 2019-06-05 Roche Innovation Center Copenhagen A/S Nucléotides et oligonucléotides de 5's-lna
US11180756B2 (en) 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
CN111819285B (zh) 2018-01-09 2024-08-09 希博斯美国有限公司 防碎基因和突变
AU2019247403B2 (en) 2018-04-04 2025-04-10 Cibus Europe, B.V. FAD2 genes and mutations
KR20220062517A (ko) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (fr) * 1986-10-28 1990-09-19 The Johns Hopkins University Alkyl- ou arylphosphonate oligonucléoside capable de réticulation avec des acides nucléiques ou de clevage d'acides nucléiques
EP0402402B1 (fr) * 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition du htlv-iii par des oligonucleotides exogenes
JPH0372493A (ja) * 1989-08-10 1991-03-27 Kikkoman Corp ２´―ｏ―置換―アデノシン―３´，５´―環状リン酸又はその塩の製法
DK0942000T3 (da) * 1989-10-24 2004-11-01 Isis Pharmaceuticals Inc 2'-modificerede oligonukleotider
US5506351A (en) * 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
DE4037363A1 (de) * 1990-04-09 1991-10-10 Europ Lab Molekularbiolog 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
JPH06256380A (ja) * 1993-03-09 1994-09-13 Toagosei Chem Ind Co Ltd ヌクレオシド誘導体ならびにリンカーを有するヌクレオシド誘導体の合成方法
DK0626387T3 (da) * 1993-05-12 1999-09-27 Novartis Ag Nukleosider og oligonukleotider med 2'-ethergrupper
DE4317323A1 (de) * 1993-05-25 1994-12-01 Bayer Ag N-(4-Fluor-phenyl)-heteroaryloxyacetamide
DE59510742D1 (de) * 1994-04-27 2003-08-14 Novartis Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen

Also Published As

Publication number Publication date
ZA953383B (en) 1995-10-27
AU1765395A (en) 1995-11-02
CA2147798A1 (fr) 1995-10-28
JPH07300493A (ja) 1995-11-14
AU682576B2 (en) 1997-10-09
EP0679657B1 (fr) 2003-07-09
US5977332A (en) 1999-11-02
IL113482A0 (en) 1995-07-31
ATE244723T1 (de) 2003-07-15
US5750673A (en) 1998-05-12
EP0679657A3 (fr) 1996-04-10
EP0679657A2 (fr) 1995-11-02
DK0679657T3 (da) 2003-10-27
CN1066456C (zh) 2001-05-30
DE59510742D1 (de) 2003-08-14
PT679657E (pt) 2003-11-28
KR950032263A (ko) 1995-12-20
ES2203635T3 (es) 2004-04-16
CN1115320A (zh) 1996-01-24

Similar Documents

Publication Publication Date Title
IL113482A0 (en) Nucleosides and oligonucleotides having 2'-ether groups
EP1013661A4 (fr) Nouveaux analogues de bicyclonucleoside et d'oligonucleotide
GB9716231D0 (en) Base analogues
EP1223173A3 (fr) Nouveaux 2'-O-alkylenucléosides et phosphoramidites, leurs procédés de préparation et leur utilisation
IL100298A (en) 3(-(2()-amino- or thiol- modified, fluorescent dye- coupled nucleosides, nucleotides and oligonucleotides, and a process for the preparation and the use thereof
EP0464638A3 (en) Oligonucleotide analogues with terminal 3'-3' or 5'-5'-internucleotide linkages
CA2278715A1 (fr) Oligonucleotides modifies par aminooxy
ES2127948T3 (es) Oligonucleotidos modificados en la posicion 2'-amido y 2'-peptido.
WO1996018634A3 (fr) Derives de nucleosides comportant des groupes protecteurs photolabiles
AU6304494A (en) Nucleosides and oligonucleotides having 2'-ether groups
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
CA2054870A1 (fr) Derives a proprietes antivirales de (phosphonomethoxy) methoxypurine/pyrimidine
SE8902568L (sv) Antiviral komposition
EP0314500A3 (en) Diagnostic probe for diabetes type 1 predisposition
AU2890497A (en) Nucleoside derivatives with photolabile protective groups
DE69632830D1 (de) Rezeptor und dafür kodierendes nukleinsäuremolekül
IL137248A0 (en) A process for the preparation of 2'-deoxy -2',2' difluoro ribozyl nucleosides and pharmaceutical compositions containing the same
GB9506644D0 (en) Preparation of nucleoside analogues
MX9701111A (es) Oligomeros especificos de union de secuencia para acidos nucleicos y su uso en estrategias antisentido.